Tisdag 9 December | 13:52:40 Europe / Stockholm

Bifogade filer

Prenumeration

Kalender

Est. tid*
2026-08-20 08:30 Kvartalsrapport 2026-Q2
2026-05-07 N/A Årsstämma
2026-04-29 08:30 Kvartalsrapport 2026-Q1
2026-02-18 08:30 Bokslutskommuniké 2025
2025-11-10 - Extra Bolagsstämma 2026
2025-11-06 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning MVIR 0.00 SEK
2025-05-07 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-18 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning MVIR 0.00 SEK
2024-05-07 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-12-01 - Extra Bolagsstämma 2024
2023-10-27 - Kvartalsrapport 2023-Q3
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning MVIR 0.00 SEK
2023-05-24 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2022-05-05 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-15 - Bokslutskommuniké 2021
2021-11-03 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2021-05-05 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-03-11 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2021-01-13 - Extra Bolagsstämma 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2020-05-05 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-27 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning MVIR 0.00 SEK
2019-05-09 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-25 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2018-05-03 - Årsstämma
2018-04-27 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-25 - Kvartalsrapport 2017-Q2
2017-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2017-05-03 - Årsstämma
2017-04-28 - Kvartalsrapport 2017-Q1
2017-03-08 - Kapitalmarknadsdag 2017
2017-02-17 - Bokslutskommuniké 2016
2017-02-02 - Extra Bolagsstämma 2017
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2016-05-03 - Årsstämma
2016-04-28 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-20 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
2015-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2015-05-05 - Årsstämma
2015-05-05 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-11-20 - Extra Bolagsstämma 2014
2014-11-20 - Kvartalsrapport 2014-Q3
2014-10-16 - Kapitalmarknadsdag 2014
2014-08-21 - Analytiker möte 2014
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-09 - X-dag ordinarie utdelning MVIR 0.00 SEK
2014-05-08 - Årsstämma
2014-05-08 - Kvartalsrapport 2014-Q1
2014-02-24 - Bokslutskommuniké 2013
2013-11-21 - Kvartalsrapport 2013-Q3
2013-10-10 - Kapitalmarknadsdag 2013
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-07 - X-dag ordinarie utdelning MVIR 0.00 SEK
2013-05-06 - Årsstämma
2013-05-06 - Kvartalsrapport 2013-Q1
2013-03-13 - 15-7 2013
2013-02-22 - Bokslutskommuniké 2012
2012-11-20 - Kvartalsrapport 2012-Q3
2012-11-19 - Kvartalsrapport 2012-Q3
2012-08-23 - Kvartalsrapport 2012-Q2
2012-05-11 - X-dag ordinarie utdelning MVIR 0.00 SEK
2012-05-10 - Årsstämma
2012-05-10 - Kvartalsrapport 2012-Q1
2012-02-22 - Bokslutskommuniké 2011
2011-11-15 - Kapitalmarknadsdag 2011
2011-10-24 - Kvartalsrapport 2011-Q3
2011-07-08 - Kvartalsrapport 2011-Q2
2011-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2011-05-05 - Årsstämma
2011-05-05 - Extra Bolagsstämma 2011
2011-05-05 - Kvartalsrapport 2011-Q1
2011-02-22 - Bokslutskommuniké 2010
2010-10-22 - Kvartalsrapport 2010-Q3
2010-07-08 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning MVIR 0.00 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-18 - Bokslutskommuniké 2009
2009-10-21 - Kvartalsrapport 2009-Q3
2009-07-09 - Kvartalsrapport 2009-Q2
2009-04-24 - X-dag ordinarie utdelning MVIR 0.00 SEK
2009-04-23 - Årsstämma
2009-04-23 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Medivir utvecklar läkemedel med fokus på cancersjukdomar där de medicinska behoven är stora. Läkemedelskandidaterna riktas mot indikationsområden där tillgängliga behandlingsmetoder är begränsade eller saknas. Medivir fokuserar på utvecklingen av fostrox, en läkemedelskandidat som har utformats för att selektivt behandla cancerceller i levern. Bolaget grundades 1988 och har huvudkontor i Huddinge.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-03 21:00:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Medivir AB (publ) (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) announces the outcome of the fully guaranteed rights issue of approximately SEK 151 million, resolved by the Company's Board of Directors on 8 October 2025 and approved by the Extraordinary General Meeting held on 10 November 2025 (the “Rights Issue”). The subscription period in the Rights Issue ended on 2 December 2025. The outcome shows that 181,669,338 ordinary shares, corresponding to approximately 54 percent of the offered ordinary shares, were subscribed for by exercise of subscription rights in the Rights Issue. Additionally, applications for subscription of 45,530,595 ordinary shares without subscription rights, corresponding to approximately 13.5 percent of the offered ordinary shares were submitted. The Rights Issue was thus subscribed for with a total of 227,199,933 ordinary shares, corresponding to approximately 67,5 percent. Accordingly, the guarantors are allotted a total of 109,303,482 ordinary shares, corresponding to approximately 32.5 percent of the Rights Issue. The Rights Issue will provide the Company with approximately SEK 151 million before deduction of transaction costs related to the Rights Issue. Of the total issue proceeds of SEK 151 million, approximately SEK 17.3 million have been set off against the Company's debt to the lender and major shareholder Linc AB. The Company thereby receives cash issue proceeds of approximately SEK 133.7 million before deduction of transaction costs. To cover any over-allotment in connection with the Rights Issue, the Company's Board of Directors has been authorised to issue additional shares corresponding to issue proceeds of up to approximately SEK 20 million (the "Over-allotment Issue"). Due to the outcome of the Rights Issue, the Over-allotment Issue will not be carried out.

Outcome of the Rights Issue

The Rights Issue encompassed 336,503,415 new ordinary shares, of which 181,669,388 ordinary shares, corresponding to approximately 54 percent of the offered ordinary shares, were subscribed for by exercise of subscription rights. In addition, applications for subscription of 45,530,595 ordinary shares without subscription rights were submitted, corresponding to approximately 13.5 percent of the offered ordinary shares. The Rights Issue is thus subscribed to approximately 67.5 percent and guarantee commitments corresponding to 109,303,482 ordinary shares, or approximately 32.5 percent, will be utilized. The subscription price was SEK 0.45 per new ordinary share. Through the Rights Issue, the share capital will increase by SEK 50,475,512.25, from SEK 17,192,695.20 to SEK 67,668,207.45, through the issuance of 336,503,415 new ordinary shares. The total number of shares will increase from 112,167,805 ordinary shares and 2,450,163 class C shares to 451,121,383 shares, of which 448,671,220 ordinary shares and 2,450,163 class C shares.


The Rights Issue provides the Company with approximately SEK 151 million before deduction of issue costs of approximately SEK 18.5 million. The costs are mainly attributable to fees to financial and legal advisors and auditors as well as remuneration to guarantors. Of the total issue proceeds of SEK 151 million, approximately SEK 17.3 million have been set off against the Company's debt to the lender and major shareholder Linc AB. The Company thereby receives cash issue proceeds of approximately SEK 133.7 million before deduction of transaction costs. The Company's board has made the assessment that the set-off is appropriate and can be carried out without being to the detriment to the Company and its creditors. The set-off does not affect the Company's use of the issue proceeds since the portion that was set off would otherwise have been used to repay the loan to Linc AB.
 

Allotment

Allotment of shares subscribed for without subscription rights will be made in accordance with the principles outlined in the disclosure document regarding the Rights Issue that was published by Medivir on 14 November 2025. Around 4 December 2025, a settlement note will be sent to those who have received allotment of shares as confirmation of the allotment of shares subscribed for without subscription rights. No confirmation will be sent to subscribers who received no allotment. Payment for subscribed and allocated shares is to be made in cash in accordance with the instructions on the settlement note sent to those who have received allotment of shares. Nominee-registered shareholders will receive notification of allotment in accordance with the respective nominee’s procedures.
 
Trading with paid subscribed shares (BTA)
The last day for trading in paid subscribed shares (BTA) will be on or about 10 December 2025. The first day of trading in the new shares on Nasdaq Stockholm is expected to be on or around 17 December 2025.
 
Lock-up undertakings
Prior to the announcement of the Rights Issue, members of the Board of Directors and shareholding members of senior management of the Company have entered into lock-up undertakings which, among other things and with customary exceptions, restrict them from selling shares in the Company. The lock-up undertakings expire 180 days after the date of this announcement of the outcome of the Rights Issue.
 
Furthermore, the Company has undertaken to DNB Carnegie Investment Bank AB and Zonda Partners AB, subject to customary exceptions, not to issue additional shares or share-related instruments for a period of 90 days following the end of the subscription period in the Rights Issue.
 
Over-allotment Issue
As the Rights Issue was not oversubscribed, the Over-allotment Issue will not be carried out. Accordingly, no directed share issue to Hallberg will be carried out.
 
Advisors
DNB Carnegie Investment Bank AB (publ) and Zonda Partners AB act as Joint Bookrunners. Advokatfirman Lindahl KB is legal advisor to the Company. DNB Carnegie Investment Bank AB (publ) also acts as issuing agent in connection with the Rights Issue.